$VXRT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Vaxart, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Vaxart, Inc.. Get notifications about new insider transactions in Vaxart, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17 2021 | VXRT | Vaxart, Inc. | Yedid Robert A. | Director | Option Exercise | A | 7.79 | 15,097 | 117,606 | 15,097 | |
| Jun 17 2021 | VXRT | Vaxart, Inc. | Finney Michael J. | Director | Option Exercise | A | 7.79 | 15,097 | 117,606 | 15,097 | |
| Jun 17 2021 | VXRT | Vaxart, Inc. | Echerd Margaret | SVP, Principal Accn ... | Option Exercise | A | 6.27 | 100,000 | 627,000 | 100,000 | |
| May 10 2021 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Option Exercise | M | 1.70 | 100,000 | 170,000 | 700,000 | |
| May 10 2021 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Option Exercise | M | 1.70 | 100,000 | 170,000 | 800,000 | |
| May 10 2021 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Sell | S | 7.13 | 100,000 | 712,750 | 0 | 100 K to 0 (-100.00 %) |
| May 10 2021 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Buy | M | 1.70 | 100,000 | 170,000 | 100,000 | 0 to 100 K |
| May 10 2021 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Sell | S | 6.54 | 100,000 | 653,890 | 0 | 100 K to 0 (-100.00 %) |
| May 10 2021 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Buy | M | 1.70 | 100,000 | 170,000 | 100,000 | 0 to 100 K |
| Mar 18 2021 | VXRT | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | M | 6.49 | 1,006 | 6,529 | 0 | |
| Mar 18 2021 | VXRT | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Buy | M | 6.49 | 1,006 | 6,529 | 48,053 | 47 K to 48.1 K (+2.14 %) |
| Mar 05 2021 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Option Exercise | M | 0.77 | 150,000 | 115,500 | 213,261 | |
| Mar 05 2021 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Sell | S | 6.04 | 150,000 | 906,450 | 0 | 150 K to 0 (-100.00 %) |
| Mar 05 2021 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Buy | M | 0.77 | 150,000 | 115,500 | 150,000 | 0 to 150 K |
| Nov 23 2020 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Sell | S | 6.32 | 333,334 | 2,108,138 | 0 | 333.3 K to 0 (-100.00 %) |
| Aug 27 2020 | VXRT | Vaxart, Inc. | WILSON KAREN J | Director | Option Exercise | A | 6.95 | 65,700 | 456,615 | 65,700 | |
| Aug 14 2020 | VXRT | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | M | 6.49 | 4,026 | 26,129 | 0 | |
| Aug 14 2020 | VXRT | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Buy | M | 6.49 | 4,026 | 26,129 | 51,679 | 47.7 K to 51.7 K (+8.45 %) |
| Aug 12 2020 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Option Exercise | X | 0.30 | 166,667 | 50,000 | 0 | |
| Aug 12 2020 | VXRT | Vaxart, Inc. | Latour Wouter | Director | Buy | X | 0.30 | 166,667 | 50,000 | 333,334 | 166.7 K to 333.3 K (+100.00 %) |
| Jun 30 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Option Exercise | X | 1.10 | 4,090,909 | 4,500,000 | 0 | |
| Jun 30 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Option Exercise | X | 0.30 | 16,666,667 | 5,000,000 | 0 | |
| Jun 30 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 8.29 | 9,385,386 | 77,804,850 | 145,523 | 9.5 M to 145.5 K (-98.47 %) |
| Jun 30 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Buy | X | 1.10 | 4,090,909 | 4,500,000 | 9,530,909 | 5.4 M to 9.5 M (+75.20 %) |
| Jun 30 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 10.38 | 18,226,667 | 189,192,803 | 5,440,000 | 23.7 M to 5.4 M (-77.01 %) |
| Jun 30 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Buy | X | 0.30 | 16,666,667 | 5,000,000 | 23,666,667 | 7 M to 23.7 M (+238.10 %) |
| Jun 17 2020 | VXRT | Vaxart, Inc. | Floroiu Cezar Andrei | Chief Executive Off ... | Option Exercise | A | 2.46 | 900,000 | 2,214,000 | 900,000 | |
| Jun 17 2020 | VXRT | Vaxart, Inc. | Floroiu Cezar Andrei | Chief Executive Off ... | Option Exercise | A | 2.46 | 845,280 | 2,079,389 | 845,280 | |
| Jun 09 2020 | VXRT | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 1.70 | 360,000 | 612,000 | 360,000 | |
| Jun 09 2020 | VXRT | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 1.70 | 900,000 | 1,530,000 | 900,000 | |
| Jun 09 2020 | VXRT | Vaxart, Inc. | Yedid Robert A. | Director | Option Exercise | A | 2.39 | 65,700 | 157,023 | 65,700 | |
| Jun 09 2020 | VXRT | Vaxart, Inc. | Finney Michael J. | Director | Option Exercise | A | 2.39 | 65,700 | 157,023 | 65,700 | |
| Jun 09 2020 | VXRT | Vaxart, Inc. | Davis Todd C | Director | Option Exercise | A | 2.39 | 65,700 | 157,023 | 65,700 | |
| Jun 09 2020 | VXRT | Vaxart, Inc. | Floroiu Cezar Andrei | Director | Option Exercise | A | 1.71 | 54,720 | 93,571 | 54,720 | |
| Jun 09 2020 | VXRT | Vaxart, Inc. | Echerd Margaret | VP, Corporate Contr ... | Option Exercise | A | 1.70 | 315,000 | 535,500 | 315,000 | |
| Jun 03 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.77 | 400,000 | 1,108,000 | 7,000,000 | 7.4 M to 7 M (-5.41 %) |
| Jun 03 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.75 | 800,000 | 2,200,000 | 7,400,000 | 8.2 M to 7.4 M (-9.76 %) |
| Jun 03 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.74 | 200,000 | 548,000 | 8,200,000 | 8.4 M to 8.2 M (-2.38 %) |
| May 29 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.61 | 200,000 | 522,000 | 8,400,000 | 8.6 M to 8.4 M (-2.33 %) |
| May 22 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.86 | 200,000 | 572,000 | 8,600,000 | 8.8 M to 8.6 M (-2.27 %) |
| May 22 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.97 | 400,000 | 1,188,000 | 8,800,000 | 9.2 M to 8.8 M (-4.35 %) |
| May 22 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 3.19 | 1,150,000 | 3,668,500 | 9,200,000 | 10.4 M to 9.2 M (-11.11 %) |
| May 18 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.86 | 650,000 | 1,859,000 | 10,350,000 | 11 M to 10.4 M (-5.91 %) |
| May 18 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.82 | 458,639 | 1,293,362 | 11,000,000 | 11.5 M to 11 M (-4.00 %) |
| May 18 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 3.02 | 834,669 | 2,520,700 | 11,458,639 | 12.3 M to 11.5 M (-6.79 %) |
| May 13 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.97 | 525,616 | 1,561,080 | 12,293,308 | 12.8 M to 12.3 M (-4.10 %) |
| May 13 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 3.02 | 1,581,076 | 4,774,850 | 12,818,924 | 14.4 M to 12.8 M (-10.98 %) |
| May 13 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.79 | 1,300,000 | 3,627,000 | 14,400,000 | 15.7 M to 14.4 M (-8.28 %) |
| May 08 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.52 | 100,000 | 252,000 | 15,700,000 | 15.8 M to 15.7 M (-0.63 %) |
| May 08 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.51 | 100,000 | 251,000 | 15,800,000 | 15.9 M to 15.8 M (-0.63 %) |
| May 08 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.58 | 50,000 | 129,000 | 15,900,000 | 16 M to 15.9 M (-0.31 %) |
| May 05 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.66 | 692,531 | 1,842,132 | 15,950,000 | 16.6 M to 16 M (-4.16 %) |
| May 05 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.65 | 957,469 | 2,537,293 | 16,642,531 | 17.6 M to 16.6 M (-5.44 %) |
| May 05 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.71 | 1,000,000 | 2,710,000 | 17,600,000 | 18.6 M to 17.6 M (-5.38 %) |
| Apr 30 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 2.96 | 4,434,296 | 13,125,516 | 18,600,000 | 23 M to 18.6 M (-19.25 %) |
| Apr 30 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 3.01 | 873,634 | 2,629,638 | 23,034,296 | 23.9 M to 23 M (-3.65 %) |
| Apr 30 2020 | VXRT | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Sell | S | 3.38 | 1,292,070 | 4,367,197 | 23,907,930 | 25.2 M to 23.9 M (-5.13 %) |
| Apr 30 2020 | VXRT | Vaxart, Inc. | Davis Todd C | Director | Sell | S | 3.28 | 60,000 | 196,500 | 120,000 | 180 K to 120 K (-33.33 %) |
| Nov 20 2019 | AVIR | Vaxart, Inc. | Yedid Robert A. | Director | Option Exercise | A | 0.31 | 54,720 | 16,963 | 54,720 | |
| Nov 20 2019 | AVIR | Vaxart, Inc. | Davis Todd C | Director | Option Exercise | A | 0.31 | 54,720 | 16,963 | 54,720 | |
| Nov 07 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Buy | P | 0.34 | 63,749 | 21,675 | 25,200,000 | 25.1 M to 25.2 M (+0.25 %) |
| Nov 07 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Buy | P | 0.34 | 61,869 | 21,035 | 25,136,251 | 25.1 M to 25.1 M (+0.25 %) |
| Nov 07 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | Director | Buy | P | 0.33 | 74,382 | 24,546 | 25,074,382 | 25 M to 25.1 M (+0.30 %) |
| Oct 15 2019 | AVIR | Vaxart, Inc. | Richard John P | Director | Buy | P | 0.38 | 20,000 | 7,680 | 20,000 | 0 to 20 K |
| Oct 07 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.37 | 290,000 | 107,300 | 25,000,000 | 24.7 M to 25 M (+1.17 %) |
| Oct 07 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.35 | 274,000 | 95,900 | 24,710,000 | 24.4 M to 24.7 M (+1.12 %) |
| Oct 03 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.34 | 228,720 | 77,765 | 24,436,000 | 24.2 M to 24.4 M (+0.94 %) |
| Oct 03 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.36 | 23,913 | 8,609 | 24,207,280 | 24.2 M to 24.2 M (+0.10 %) |
| Oct 03 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.35 | 183,367 | 64,178 | 24,183,367 | 24 M to 24.2 M (+0.76 %) |
| Sep 30 2019 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | P | 0.30 | 166,667 | 50,000 | 166,667 | |
| Sep 30 2019 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Buy | P | 0.30 | 166,667 | 50,000 | 166,667 | 0 to 166.7 K |
| Sep 30 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.33 | 1,600,376 | 528,124 | 24,000,000 | 22.4 M to 24 M (+7.14 %) |
| Sep 30 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.33 | 1,600,376 | 528,124 | 24,000,000 | 22.4 M to 24 M (+7.14 %) |
| Sep 30 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.29 | 972,643 | 282,066 | 22,399,624 | 21.4 M to 22.4 M (+4.54 %) |
| Sep 30 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.29 | 972,643 | 282,066 | 22,399,624 | 21.4 M to 22.4 M (+4.54 %) |
| Sep 30 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.28 | 4,760,314 | 1,332,888 | 21,426,981 | 16.7 M to 21.4 M (+28.56 %) |
| Sep 30 2019 | AVIR | Vaxart, Inc. | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 0.28 | 4,760,314 | 1,332,888 | 21,426,981 | 16.7 M to 21.4 M (+28.56 %) |
| Jun 14 2019 | AVIR | Vaxart, Inc. | VANLENT ANNE | Director | Option Exercise | A | 0.68 | 12,700 | 8,636 | 12,700 | |
| Jun 14 2019 | AVIR | Vaxart, Inc. | VANLENT ANNE | Director | Option Exercise | A | 0.68 | 9,000 | 6,120 | 9,000 | |
| Jun 14 2019 | AVIR | Vaxart, Inc. | Markham Richard J | Director | Option Exercise | A | 0.68 | 12,700 | 8,636 | 12,700 | |
| Jun 14 2019 | AVIR | Vaxart, Inc. | Markham Richard J | Director | Option Exercise | A | 0.68 | 9,000 | 6,120 | 9,000 | |
| Jun 14 2019 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Option Exercise | A | 0.68 | 12,700 | 8,636 | 12,700 | |
| Jun 14 2019 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Option Exercise | A | 0.68 | 9,000 | 6,120 | 9,000 | |
| Jun 14 2019 | AVIR | Vaxart, Inc. | COX GEOFFREY F | Director | Option Exercise | A | 0.68 | 12,700 | 8,636 | 12,700 | |
| Jun 14 2019 | AVIR | Vaxart, Inc. | COX GEOFFREY F | Director | Option Exercise | A | 0.68 | 9,000 | 6,120 | 9,000 | |
| Jun 14 2019 | AVIR | Vaxart, Inc. | Richard John P | Director | Option Exercise | A | 0.68 | 12,700 | 8,636 | 12,700 | |
| Jun 14 2019 | AVIR | Vaxart, Inc. | Richard John P | Director | Option Exercise | A | 0.68 | 9,000 | 6,120 | 9,000 | |
| May 14 2019 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 0.77 | 124,061 | 95,527 | 124,061 | |
| May 14 2019 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 0.77 | 363,261 | 279,711 | 363,261 | |
| May 14 2019 | AVIR | Vaxart, Inc. | Echerd Margaret | VP, Corporate Contr ... | Option Exercise | A | 0.77 | 70,444 | 54,242 | 70,444 | |
| Apr 12 2019 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | P | 1.10 | 27,273 | 30,000 | 27,273 | |
| Apr 12 2019 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Buy | P | 1.10 | 27,273 | 30,000 | 52,661 | 25.4 K to 52.7 K (+107.42 %) |
| Apr 12 2019 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Option Exercise | P | 1.10 | 181,818 | 200,000 | 181,818 | |
| Apr 12 2019 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Buy | P | 1.10 | 181,818 | 200,000 | 452,572 | 270.8 K to 452.6 K (+67.15 %) |
| Feb 06 2019 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Buy | J | 0.00 | 34,958 | 0 | 270,754 | 235.8 K to 270.8 K (+14.83 %) |
| Sep 24 2018 | AVIR | Vaxart, Inc. | Harland John M | Chief Financial Off ... | Buy | J | 0.00 | 761 | 0 | 761 | 0 to 761 |
| Jun 08 2018 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Buy | P | 2.91 | 800 | 2,328 | 233,978 | 233.2 K to 234 K (+0.34 %) |
| Jun 08 2018 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Buy | P | 2.92 | 1,135 | 3,314 | 233,178 | 232 K to 233.2 K (+0.49 %) |
| Jun 08 2018 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Buy | P | 2.91 | 65 | 189 | 232,043 | 232 K to 232 K (+0.03 %) |
| Jun 08 2018 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Buy | P | 3.46 | 2,000 | 6,920 | 231,978 | 230 K to 232 K (+0.87 %) |
| Jun 08 2018 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Buy | P | 4.27 | 1,000 | 4,270 | 229,978 | 229 K to 230 K (+0.44 %) |
| May 29 2018 | AVIR | Vaxart, Inc. | Harland John M | Chief Financial Off ... | Option Exercise | A | 5.17 | 18,000 | 93,060 | 18,000 | |
| May 29 2018 | AVIR | Vaxart, Inc. | Harland John M | Chief Financial Off ... | Option Exercise | A | 5.17 | 18,000 | 93,060 | 18,000 | |
| May 29 2018 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 5.17 | 110,700 | 572,319 | 110,700 | |
| May 29 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 5.17 | 14,000 | 72,380 | 14,000 | |
| May 29 2018 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 5.17 | 110,700 | 572,319 | 110,700 | |
| May 29 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 5.17 | 14,000 | 72,380 | 14,000 | |
| Mar 14 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | M | 6.49 | 2,013 | 13,064 | 0 | |
| Mar 14 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Buy | M | 6.49 | 2,013 | 13,064 | 47,653 | 45.6 K to 47.7 K (+4.41 %) |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 4.07 | 9,060 | 36,874 | 9,060 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 12.98 | 7,731 | 100,348 | 7,731 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 17.49 | 10,067 | 176,072 | 10,067 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 8.03 | 11,604 | 93,180 | 11,604 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 6.49 | 10,523 | 68,294 | 10,523 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 8.03 | 3,020 | 24,251 | 3,020 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 6.49 | 1,006 | 6,529 | 1,006 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 6.49 | 4,027 | 26,135 | 4,027 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Option Exercise | A | 6.49 | 2,014 | 13,071 | 2,014 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Grant | A | 0.00 | 25,388 | 0 | 25,388 | 0 to 25.4 K |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Grant | A | 0.00 | 9,060 | 0 | 9,060 | 0 to 9.1 K |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Tucker Sean | Chief Scientific Of ... | Grant | A | 0.00 | 45,640 | 0 | 45,640 | 0 to 45.6 K |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 4.07 | 23,651 | 96,260 | 23,651 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 12.98 | 10,731 | 139,288 | 10,731 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 17.49 | 18,120 | 316,919 | 18,120 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 8.03 | 14,908 | 119,711 | 14,908 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 6.49 | 13,256 | 86,031 | 13,256 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 8.03 | 9,442 | 75,819 | 9,442 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Latour Wouter | President and Chief ... | Option Exercise | A | 8.03 | 6,536 | 52,484 | 6,536 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Harland John M | Chief Financial Off ... | Option Exercise | A | 4.07 | 7,047 | 28,681 | 7,047 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Harland John M | Chief Financial Off ... | Option Exercise | A | 12.98 | 4,087 | 53,049 | 4,087 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Harland John M | Chief Financial Off ... | Option Exercise | A | 17.49 | 8,255 | 144,380 | 8,255 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Harland John M | Chief Financial Off ... | Option Exercise | A | 8.03 | 9,563 | 76,791 | 9,563 | |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Finney Michael J. | Director | Grant | A | 0.00 | 228,978 | 0 | 228,978 | 0 to 229 K |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Care Capital III LLC | 10% Owner | Grant | A | 0.00 | 30,793,670 | 0 | 30,793,670 | 0 to 30.8 M |
| Feb 15 2018 | AVIR | Vaxart, Inc. | Markham Richard J | Director | Grant | A | 0.00 | 30,793,670 | 0 | 30,793,670 | 0 to 30.8 M |
| Feb 15 2018 | AVIR | Vaxart, Inc. | LESCHLY JAN | Director | Grant | A | 0.00 | 30,793,670 | 0 | 30,793,670 | 0 to 30.8 M |
| May 22 2017 | AVIR | Aviragen Therapeut ... | ANIDO ARMANDO | Director | Option Exercise | A | 0.49 | 20,000 | 9,800 | 75,000 | |
| May 22 2017 | AVIR | Aviragen Therapeut ... | COX GEOFFREY F | Director | Option Exercise | A | 0.49 | 20,000 | 9,800 | 103,332 | |
| May 22 2017 | AVIR | Aviragen Therapeut ... | DOUGHERTY MICHAEL R | Director | Option Exercise | A | 0.49 | 20,000 | 9,800 | 105,000 | |
| May 22 2017 | AVIR | Aviragen Therapeut ... | Dunne Michael W. | Director | Option Exercise | A | 0.49 | 20,000 | 9,800 | 75,000 | |
| May 22 2017 | AVIR | Aviragen Therapeut ... | Richard John P | Director | Option Exercise | A | 0.49 | 20,000 | 9,800 | 105,000 | |
| May 22 2017 | AVIR | Aviragen Therapeut ... | PLUMB RUSSELL H | Director | Option Exercise | A | 0.49 | 20,000 | 9,800 | 622,453 | |
| May 22 2017 | AVIR | Aviragen Therapeut ... | VANLENT ANNE | Director | Option Exercise | A | 0.49 | 20,000 | 9,800 | 105,000 | |
| Apr 05 2017 | AVIR | Aviragen Therapeut ... | COLONNESE MARK P | Chief Financial Off ... | Option Exercise | A | 0.66 | 400,000 | 262,400 | 775,000 | |
| Apr 05 2017 | AVIR | Aviragen Therapeut ... | PATTI JOSEPH M | CEO | Option Exercise | A | 0.66 | 650,000 | 426,400 | 2,113,304 | |
| Aug 12 2016 | NABI | Aviragen Therapeut ... | PATTI JOSEPH M | CEO | Option Exercise | A | 1.30 | 380,000 | 494,000 | 1,478,929 | |
| Jul 29 2016 | NABI | Aviragen Therapeut ... | COLONNESE MARK P | CFO and EVP | Option Exercise | A | 1.34 | 150,000 | 201,000 | 375,000 | |
| May 13 2016 | NABI | Aviragen Therapeut ... | ANIDO ARMANDO | Director | Option Exercise | A | 1.50 | 20,000 | 30,000 | 20,000 | |
| May 13 2016 | NABI | Aviragen Therapeut ... | COX GEOFFREY F | Director | Option Exercise | A | 1.50 | 20,000 | 30,000 | 20,000 | |
| May 13 2016 | NABI | Aviragen Therapeut ... | DOUGHERTY MICHAEL R | Director | Option Exercise | A | 1.50 | 20,000 | 30,000 | 20,000 |